Abstract
The homozygosity of the 10-repeat allele at dopamine transporter gene (DAT1) seems to be associated with a poor response to methylphenidate (MPH) in children with attention-deficit/hyperactivity disorder (ADHD). This pilot study aimed to simultaneously assess polymorphisms at DAT1, response to MPH, and neuroimaging. Only ADHD children with at least a moderate response to MPH were included. Significantly higher regional cerebral blood flows assessed by single photon emission computerized tomography (SPECT) were detected in medial frontal and left basal ganglia areas in children with homozygosity for the 10-repeat allele at DAT1 gene (n = 4) than in children without this genotype (n = 4) (P < 0.05). These findings provide a preliminary connection between pharmacogenetics and neurobiological investigations on stimulant treatment of ADHD.
Copyright 2003 Wiley-Liss, Inc.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Attention Deficit Disorder with Hyperactivity / diagnostic imaging
-
Attention Deficit Disorder with Hyperactivity / drug therapy*
-
Attention Deficit Disorder with Hyperactivity / genetics*
-
Cerebrovascular Circulation / drug effects*
-
Cerebrovascular Circulation / genetics*
-
Cerebrovascular Circulation / physiology
-
Child
-
Dopamine Plasma Membrane Transport Proteins
-
Gene Frequency
-
Humans
-
Male
-
Membrane Glycoproteins*
-
Membrane Transport Proteins / genetics*
-
Methylphenidate / pharmacology
-
Methylphenidate / therapeutic use*
-
Nerve Tissue Proteins*
-
Pilot Projects
-
Statistics, Nonparametric
-
Tomography, Emission-Computed, Single-Photon / methods
Substances
-
Dopamine Plasma Membrane Transport Proteins
-
Membrane Glycoproteins
-
Membrane Transport Proteins
-
Nerve Tissue Proteins
-
SLC6A3 protein, human
-
Methylphenidate